Targeting p21 for diabetes: Another choice of senotherapy

Hiroshi Kondoh; Eiji Hara

doi:10.1016/j.cmet.2021.12.008

Targeting p21 for diabetes: Another choice of senotherapy

Cell Metab. 2022 Jan 4;34(1):5-7. doi: 10.1016/j.cmet.2021.12.008.

Authors

Hiroshi Kondoh¹, Eiji Hara²

Affiliations

¹ Geriatric Unit, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan. Electronic address: [email protected].
² Research Institute for Microbial Diseases, Osaka University, Suita 565-0871, Japan; Immunology Frontier Research Center, Osaka University, Suita 565-0871, Japan; Center for Infectious Diseases Education and Research, Osaka University, Suita 565-0871, Japan. Electronic address: [email protected].

PMID: 34986338
DOI: 10.1016/j.cmet.2021.12.008

Abstract

Senotherapy, the elimination of senescent cells, is a cutting-edge treatment for aging-related and lifestyle diseases. In this issue of Cell Metabolism, Wang et al. report that p21^Cip1 highly expressing cells, which represent a senescent cell population, occur in the adipose tissue during obesity. Targeting them genetically or pharmacologically attenuates insulin resistance, suggesting a possible therapeutic approach to treat the metabolic complications of obesity.

Publication types

Comment

MeSH terms

Adipose Tissue
Aging
Cellular Senescence
Diabetes Mellitus*
Humans
Insulin Resistance*